Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cassiopea S.p.A.
Apparently positive news for two unglamorous indications – acne and allergy – should be balanced against restrictive reimbursement and market fragmentation.
Keeping Track: US FDA Has Clinical Questions For Tricida, Gilead And BioMarin; Enspryng And Winlevi Approved
The latest drug approval and decision news from the Pink Sheet’s US FDA Performance Tracker.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
The latest drug development news and highlights from our US FDA Performance Tracker.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Cassiopea, Inc.